Understand the source comparison
Adamax Benefits Comparison: AMPK Activators in Research
Understanding where Adamax sits among other metabolic peptides and AMPK-activating compounds requires direct comparison across mechanism, dosing, and observed outcomes. Adamax Peptide Direct AMPK phosphorylation at alpha-2 subunit 500–750 mcg/kg daily 18–24% v
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding where Adamax sits among other metabolic peptides and AMPK-activating compounds requires direct comparison across mechanism, dosing, and observed outcomes.
- Adamax Peptide
- Direct AMPK phosphorylation at alpha-2 subunit
- 500–750 mcg/kg daily
- 18–24% visceral fat reduction over 4–6 weeks in obese rodent models
- HOMA-IR improvement of 28–35%
- Most specific for visceral adipose targeting; mechanism bypasses hormone intermediaries, reducing variability in response
- AOD9604
- Fragment of hGH C-terminus; lipolytic without GH receptor binding
- 300–500 mcg/kg daily
- 12–16% total fat reduction; less visceral-specific
- Minimal direct effect on insulin signaling
- Effective for generalized fat loss but lacks the metabolic switching and insulin sensitization seen with AMPK activators
- Metformin
- AMPK activation via inhibition of mitochondrial complex I
- 250–500 mg/kg daily (rodent equivalent of 1500–2000 mg human dose)
- 5–9% fat reduction in diet-induced obesity models
- Moderate improvement; HOMA-IR reduction ~18–22%
- Proven clinical track record but lower potency per dose compared to peptide-based AMPK activators; gastrointestinal side effects limit tolerability
- Tesofensine
- Monoamine reuptake inhibitor; increases norepinephrine, dopamine, serotonin
- 1–3 mg/kg daily
- 15–22% total fat reduction driven by appetite suppression and thermogenesis
- Indirect via weight loss rather than direct AMPK or insulin pathway modulation
- Potent for appetite-driven weight loss but mechanism is central rather than peripheral; does not improve metabolic flexibility independent of caloric deficit
- AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide)
- AMPK activator via mimicking AMP accumulation
- 500 mg/kg daily (high dose due to poor bioavailability)
- 10–14% fat reduction; less consistent across studies
- Moderate insulin sensitization but with high inter-individual variability
- Proof-of-concept AMPK activator but impractical dosing and significant off-target effects limit research utility compared to peptide-based alternatives
- The Adamax benefits profile. Particularly the visceral fat specificity and robust insulin sensitivity improvements. Position it as a more targeted tool than broad-spectrum appetite suppressants or older AMPK activators with dosing limitations. Researchers comparing outcomes across our full peptide collection consistently note that compounds with direct enzymatic targets (like Adamax's AMPK phosphorylation) produce more reproducible results than those relying on receptor-mediated cascades with multiple regulatory checkpoints.